AKT1 and prostate carcinoma: Consistently, p53 was shown to functionally impact the response of H226 cells to EGFR blockade [54], and the restoration of p53 function in p53 null prostate cancer cells stimulates EGFR and Akt phosphorylation and restores sensitivity to cetuximab [55].